According to the American Cancer Society, lung cancer is the leading cause of cancer deaths in both men and women in the United States, with approximately 155,000 deaths each year. Although the survival rate is 49 percent for cases detected when the disease is still localized, only 16 percent of lung cancer cases are diagnosed at this early stage. Recently, almost 7 percent of 1,000 healthy volunteers in New York who participated in the Early Lung Cancer Action Project were found to have between one and three nodules on baseline screening X-rays.

Co-authors of "A Comparison of the Diagnostic Accuracy of F18-FDG PET and CT in the Characterization of Solitary Pulmonary Nodules" include Fletcher; Steven M. Kymes, department of ophthalmology and visual sciences, Washington University School of Medicine, St. Louis, Mo.; Michael Gould, department of Veterans Affairs, Palo Alto Health Care System and department of medicine; George Segall, department of Veterans Affairs, Palo Alto Health Care System and department of radiology, Stanford School of Medicine, Stanford, Calif.; Naomi Alazraki, department of radiology, Emory University School of Medicine, Atlanta, Ga.; R. Edward Coleman, department of radiology, Duke University School of Medicine, Durham, N.C.; Val. J. Lowe, department of radiology, Mayo Clinic, Rochester, Minn.; Charles Marn, department of radiology and Lyn A. Thet, department of medicine, University of Wisconsin School of Medicine, Madison, Wis.; Kelvin Lee, department of Veterans Affairs, Cooperative Studies Program Coordinating Center, Palo Alto, Calif.


Credentialed media: To obtain a copy of this article-and online access to the Journal of Nuclear Medicine- please contact Kathryn Wiley by phone at (703) 326-1184 or send an e-mail to kwiley@snm.org. Current and past issues of the Journal of Nuclear Medicine can be found online at jnm.snmjournals.org. Print copies can be obtained by contacting the SNM Service Center, 1850 Samuel Morse Drive, Reston, VA 20190-5316; phone (800) 513-6853; e-mail servicecenter@snm.org; fax (703) 708-9015. A subscription to the journal is an SNM member benefit.

About SNM-Advancing Molecular Imaging and Therapy
SNM is an international scientific and professional organization of more than 16,000 members dedicated to promoting the science, technology and practical applications of molecular and nuclear imaging to diagnose, manage and treat diseases in women, men and children. Founded more than 50 years ago, SNM continues to provide essential resources for health care practitioners and patients; publish the most prominent peer-reviewed journal in the field (Journal of Nuclear Medicine); host the premier annual meeting for medical imaging; sponsor research grants, fellowships and awards; and train physicians, technologists, scientists, physicists, chemists and radiopharmacists in state-of-the-art imaging procedures and advances. SNM members have introduced-and continue to explore-biological and technological innovations in medicine that noninvasively investigate the molecular basis of diseases, benefiting countless generations of patients. SNM is based in Reston, Va.; additional information can be found online at http://www.snm.org.

Back to HCB News

More Industry Headlines